| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,370,000 |
| Market
Cap: |
776.74(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0401 - $1.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cleland Jeffrey L |
President and CEO |
• • – |
2014-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,900 |
105,272 |
|
- |
|
| Yucca (jersey) Slp |
10% Owner |
– – • |
2014-11-13 |
4 |
S |
$19.43 |
$241,698 |
D/D |
(12,438) |
21,116 |
|
- |
|
| Yucca (jersey) Slp |
10% Owner |
– – • |
2014-11-12 |
4 |
S |
$19.42 |
$703,040 |
D/D |
(36,200) |
21,215 |
|
- |
|
| Ratcliffe Liam |
10% Owner |
– – • |
2014-11-11 |
4 |
S |
$19.37 |
$15,496,000 |
D/D |
(800,000) |
2,559,374 |
|
- |
|
| Ratcliffe Liam |
10% Owner |
– – • |
2014-09-29 |
4 |
S |
$20.02 |
$251,331 |
D/D |
(12,556) |
3,359,374 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2014-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
17,500 |
|
- |
|
| Brumm Joshua T |
Chief Financial Officer |
• – – |
2014-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
25,000 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2014-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
146,280 |
|
- |
|
258 Records found
|
|
Page 11 of 11 |
|
|
